Alteplase
Alteplase has been studied in 10 papers since 2015: 3 trials and 6 observational studies in people, 1 review. The newest paper, Sep 2, 2025: “Brain Frailty and Functional Outcomes After Thrombolysis for Acute Ischemic Stroke”.
10 papers study itUpdated
- 57 trials, none about aging, 17 with no results posted
- Human trial3
- Humans6
Has Alteplase been tested in people?
0 about aging, of 57Yes: 3 trials and 6 observational studies in people have been published, and 57 trials are registered.
In trials
Phase 4Results posted12 trials
Phase 4Results posted10 trials
Phase 4Active, not recruiting5 trials
Phase 4Results posted3 trials
Phase 4Terminated3 trials
Phase 4Results posted3 trials
All 37Fewer
Stopped
NCT03988842TerminatedPulmonary embolism
COVID-19 pandemic
NCT00303420TerminatedThrombosis
Unable to enrol enough people to achieve the full sample size
NCT01576679TerminatedAbdominal Abscess
very slow accrual.
NCT03187405TerminatedIntracranial aneurysm
lack of patient
NCT02492477TerminatedSolid tumor
poor recruitment
Who is developing Alteplase?
2 companies: Tanabe Pharma and Boehringer Ingelheim.
Trial sponsors
Company2 trialsPhase 4613 people
Company2 trialsPhase 4231 people
Company2 trialsPhase 4161 people
Company3 trialsPhase 3254 people
Company1 trialPhase 3310 people
Company1 trialPhase 2266 people
Company1 trialPhase 2
Sahlgrenska Universitetssjukhuset
1 trialPhase 4400 people